**Table S2. Clinical and tumor characteristics of the IHC cohort (n=102)24-27, 56**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variables** | **No. (%)** | **Variables** | **No. (%)** |
| Sex |  | Metastasis\* |  |
| Female  | 18(17.6) | No | 98(96.1) |
| Male  | 84(82.4) | Yes | 4(3.9) |
| Age, mean, years | 62.7 | Postoperative treatment^24, 27 |  |
| <70 | 79(77.5) |  Not receive | 35 (34.3) |
| ≥70 | 23(22.5)  |  Chemotherapy | 40 (39.2) |
| Smoking history |  |  Radiotherapy | 1 (1) |
| Non-smoker | 58(56.9) |  Chemotherapy plus radiotherapy | 26 (25.5) |
| Smoker | 44(43.1) | Postoperative adjuvant chemotherapy26, 56 |  |
| SCLC TNM staging# |  | Yes | 54 (52.9) |
| I-II | 60(58.8) | No | 48 (47.1) |
| III | 42(41.2) |  |  |
| T stage # |  |  |  |
| T1-2 | 87(85.3) |  |  |
| T3-4 | 15(14.7) |  |  |
| N stage # |  |  |  |
| N0-1 | 67(65.7) |  |  |
| N2-3 | 35(34.3) |  |  |

Abbreviation: IHC, immunohistochemistry; N, lymph node; SCLC, small cell lung cancer; T, tumor, TNM, tumor-node-metastasis.

#Pathological stage.

\*Clinical stage: metastasis considered by clinical imaging before surgery.

^ All treatment after surgery.